BerGenBio Third Quarter Results 2024 ...Middle East

PR Newswire - News
BERGEN, Norway, Nov. 13, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended September 30, 2024,...

Read More Details
Finally We wish PressBee provided you with enough information of ( BerGenBio Third Quarter Results 2024 )

Also on site :